Dr. Cortés, researcher in the Neuromuscular Disease Unit, Neurology Service, Hospital de la Santa Creu i Sant Pau, is the first author of the article “Clinical characteristics of double-seronegative Patients with Myasthenia Gravis and antibodies to Cortactin”, published in JAMA Neurology. This article focuses on Cortactin identifications, a new antigen in seronegative myasthenia gravis. The presence of the antibodies anti-Cortactin is a biomarker in seronegative myasthenia and suggest the disease will be eye-restricted or mild generalized. These antibodies are a new diagnostic tool useful in the diagnosis and clinical management of these patients.
